Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 6Phase 1 5Phase 1/2 4Phase 2/3 2Phase 4 1

Status

Completed 25Active not recruiting 8Terminated 6Recruiting 4Unknown 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Neoplasms 1

Interventions

pembrolizumab 109Cyclophosphamide 89fludarabine 70Carboplatin 57Injections 56Bevacizumab 49Specimen Handling 43Gemcitabine 41Magnetic Resonance Spectroscopy 40Paclitaxel 39Nivolumab 38venetoclax 36Dexamethasone 35Cisplatin 34Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Capecitabine 27Oxaliplatin 26Fluorouracil 26Pemetrexed 24Irinotecan 24Azacitidine 24abemaciclib 23toripalimab 22Fulvestrant 22fludarabine phosphate 21Rituximab 21Leucovorin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × carfilzomib × Clear all
NCT07479979 2026-05-14

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Hoosier Cancer Research Network

Phase 1/2 Recruiting
62 enrolled
Plasma cell

Multiple Myeloma

NCT04973605 2026-05-11

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

BeOne Medicines

Phase 1/2 Recruiting
246 enrolled
Plasma cell

Multiple Myeloma

NCT05199311 2026-02-18

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

Hackensack Meridian Health

Phase 1/2 Recruiting
66 enrolled
Plasma cell

Multiple Myeloma

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

AbbVie

Phase 1/2 Recruiting
440 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡